Last reviewed · How we verify
NCT06248918: WATSOCPAP
Nurse-led Physical Activity Program Among Breast Cancer Survivors
NA trial testing WATSOCPAP in Breast Cancer Female in 84 participants. Status unknown.
1 September 2024
Quick facts
| Lead sponsor | Istanbul Medipol University Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 84 |
| Start date | 1 March 2024 |
| Primary completion | 1 September 2024 |
| Estimated completion | 1 October 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- WATSOCPAP
Conditions studied
- Breast Cancer Female — all drugs for Breast Cancer Female →
- Survivorship — all drugs for Survivorship →
- Health Behavior — all drugs for Health Behavior →
Sponsor
Istanbul Medipol University Hospital
Who can join
Adults 18 to 65, female only, with Breast Cancer Female or Survivorship. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A nurse-led physical activity program including an individualized exercise program using wearable technology and health coaching based on Social Cognitive Theory will be implemented for women surviving cancer. The impact of the nurse-led physical activity program on physical activity level, health-related quality of life and cognitive factors (self regulation, outcome expectation, self efficacy, perceived social support, perceived environment) will be evaluated in the study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06248918
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer Female
Currently open trials in the same condition.
- NCT07505797 — ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) · recruiting
- NCT07198724 — ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrin · Phase 1, PHASE2 · recruiting
- NCT07331506 — Validation of the Oncoliq Test for the Early Detection of Breast Cancer. · recruiting
- NCT07214883 — UCF MammoChat: Image Repository · recruiting
- NCT07120100 — Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Surviv · NA · recruiting
Other Istanbul Medipol University Hospital trials
Trials by the same sponsor.
- NCT07508371 — Menthol Massage for Post-Bypass Pain & Anxiety · NA · not yet recruiting
- NCT07575477 — Comparison Of Early Mobilization And Electrical Stimulation On Functional Recovery After Lumbar Disc Herniation Surgery · NA · not yet recruiting
- NCT07525115 — Effects of Proprioceptive Neuromuscular Facilitation-Based Lower Extremity Training on Balance, Gait, and Functional Ind · NA · not yet recruiting
- NCT07467278 — Low-FODMAP Diet and Intestinal Permeability in Patients With Irritable Bowel Syndrome · NA · not yet recruiting
- NCT07468864 — Validity of the Turkish Situational Vertigo Questionnaire · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06248918 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istanbul Medipol University Hospital
- Last refreshed: 18 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06248918.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing